Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 6 Neoplasms 3 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma 1 Head and Neck Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 67 Dexamethasone 52 Peripheral Blood Stem Cell Transplantation 37 Lenalidomide 37 Rituximab 35 fludarabine phosphate 34 Bortezomib 30 Filgrastim 27 Etoposide 27 Cytarabine 25 Carboplatin 25 Busulfan 23 Radiotherapy 22 Melphalan 22 Gemcitabine 22 Cyclosporine 21 pomalidomide 20 fludarabine 20 Whole-Body Irradiation 20 Mycophenolic Acid 20 Paclitaxel 19 Methotrexate 18 venetoclax 17 Cisplatin 17 pembrolizumab 16 Calcium Dobesilate 16 Bevacizumab 16 Tacrolimus 14 Antilymphocyte Serum 14 Nivolumab 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Recurrence × rovalpituzumab tesirine × Clear all

NCT02674568 2021-07-30

TRINITY

AbbVie

Phase 2 Completed

342 enrolled 18 charts

Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡